2020
Reduced 2-year aneurysm retreatment and costs among patients treated with flow diversion versus non-flow diversion embolization: A Premier Healthcare Database retrospective cohort study
Grandhi R, Karsy M, Taussky P, Ricker CN, Malhotra A. Reduced 2-year aneurysm retreatment and costs among patients treated with flow diversion versus non-flow diversion embolization: A Premier Healthcare Database retrospective cohort study. PLOS ONE 2020, 15: e0234478. PMID: 32555657, PMCID: PMC7302520, DOI: 10.1371/journal.pone.0234478.Peer-Reviewed Original ResearchConceptsPipeline Embolization DeviceEndovascular treatmentRetreatment ratePS matchingIntracranial aneurysmsRetrospective cohort studyRate of readmissionEmergency department visitsLength of stayLower retreatment rateInitial treatment costsUnruptured intracranial aneurysmsPropensity-score matchingTime of treatmentCumulative followCohort studyReadmission costsDepartment visitsPatient subgroupsPED placementCase selection biasSame hospitalAneurysm retreatmentEmbolization DevicePatients
2018
Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients
Cheng JY, Li FY, Ko CJ, Colegio OR. Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients. JAMA Dermatology 2018, 154: 60-66. PMID: 29167858, PMCID: PMC5833573, DOI: 10.1001/jamadermatol.2017.4506.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAge DistributionAgedCarcinoma, Squamous CellCohort StudiesFemaleHumansImmunocompetenceIncidenceMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingOrgan TransplantationPrognosisRetrospective StudiesRisk AssessmentSex DistributionSkin NeoplasmsTransplant RecipientsUnited StatesConceptsSolid organ transplant recipientsSquamous cell carcinomaImmunocompetent control groupOrgan transplant recipientsImmunocompetent patientsTransplant recipientsImmunocompetent individualsMean ageCell carcinomaOutcome measuresControl groupStudy participantsCutaneous squamous cell carcinomaAggressive squamous cell carcinomaAnnual biopsy rateImmunosuppressive medication regimenRetrospective cohort studyDisease-specific deathSecondary outcome measuresPrimary outcome measureAggressive behaviorCumulative followOverall deathCohort studyImmunocompetent group
2017
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Journal Of Neurosurgery 2017, 128: 1102-1114. PMID: 28621624, DOI: 10.3171/2016.11.jns16973.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overBrain NeoplasmsCohort StudiesDNA Mutational AnalysisFemaleGenetic MarkersGliomaHumansIsocitrate DehydrogenaseKaplan-Meier EstimateKi-67 AntigenMaleMiddle AgedMutationPromoter Regions, GeneticSurvival AnalysisTelomeraseTreatment OutcomeYoung AdultConceptsMolecular subsetsIDH-wt gliomasIDH wild-type diffuse gliomasDiffuse gliomasIDH-mut gliomasClinical behaviorTERTp-mutHigh Ki-67 labeling indexKi-67 labeling indexDouble-negative subsetObjective Recent studiesClinical tumor behaviorDifferent tumor biologySpecific molecular subsetsTERT promoter mutationsEpidermal growth factor receptorTensin homolog (PTEN) mutationsTelomerase promoter mutationsCumulative followGrowth factor receptorSurgical cohortMalignant degenerationClinical parametersHistopathological diagnosisCombined status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply